Form 4: Vertex Pharmaceuticals EVP and CMO, Carmen Bozic, Reports Stock Disposal
SEC Form 4 Filing
Carmen Bozic, EVP and CMO of Vertex Pharmaceuticals, disposed of 4,962 shares of common stock on February 26, 2025, to cover tax obligations.
Summary
- On February 26, 2025, Carmen Bozic, the Executive Vice President and Chief Medical Officer (EVP and CMO) of Vertex Pharmaceuticals, disposed of 4,962 shares of the company's common stock.
- The transaction was executed at a price of $479.61 per share.
- Following the transaction, Bozic directly owns 32,669 shares of Vertex Pharmaceuticals.
- The transaction was reported on February 28, 2025.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock disposal, likely for tax purposes. It doesn't inherently indicate positive or negative company performance.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. This filing indicates a disposal of shares by an executive, which could be for various reasons, including tax obligations or portfolio diversification.
Stakeholder Impact
- The disposal of shares by an executive could be perceived neutrally or slightly negatively by shareholders, depending on the context and the size of the transaction.
Key Dates
| Date | Description |
|---|---|
| 02/26/2025 | Date of stock disposal transaction. |
| 02/28/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.